Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma

doi:10.3748/wjg.v21.i42.12059

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 42

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9400)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-1) series.

Item

Count

PDF

759

WORD

238

HTML

5445

Figures (1-1)

264

Tables (1-1)

214

Sum=6920

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1038

Download

1441

Sum=2479

Nov 14, 2015 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (51)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Nov 14, 2015; 21(42): 12059-12070
Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.12059

Table 1 Landscape of sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma

Combined drugs	Treatment modality	Current stage	Outcome	Ref.
Antiangiogenic agents
Dalantercept	Simultaneous combination with sorafenib	Phase Ib (ongoing)	Awaited	NCT02024087
Axitinib	Sequential treatment after sorafenib failing	Phase II (finished)	Warranting further clinical study	[49]
	Sequential treatment after sorafenib failing	Phase II (ongoing)	Awaited	EUCTR2011-002029-24-IT
Apatinib	Sequential treatment after sorafenib failing	Phase III (ongoing)	Awaited	NCT02329860
MEK/ERK inhibitors
AZD6244	Simultaneous combination with sorafenib	Phase II (terminated)	Unknown	NCT01029418
Refametinib	Simultaneous combination with sorafenib	Phase II (finished)	Warranting further clinical study	[64]
mTOR inhibitors
Sirolimus	Simultaneous combination with sorafenib	Preclinical study	Synergistic effect	[73]
Everolimus	Simultaneous combination with sorafenib	Phase II (ongoing)	Awaited	NCT01005199
Temsirolimus	Simultaneous combination with sorafenib	Phase II (ongoing)	Awaited	NCT01687673
PI-103	Simultaneous combination with sorafenib	Preclinical study	Synergistic effect	[86]
PKI-587	Simultaneous combination with sorafenib	Preclinical study	Synergistic effect	[87]
HDACs inhibitors
Panobinostat	Simultaneous combination with sorafenib	Phase I (terminated)	Precluding phase II studies	NCT00873002
Vorinostat	Simultaneous combination with sorafenib	Phase I (suspended)	Unknown	NCT01075113
Resminostat	Simultaneous combination with sorafenib	Phase II (finished)	Warranting further clinical study	[100]
	Simultaneous combination with sorafenib	Phase I/II (ongoing)	Awaited	NCT02400788
MPT0E028	Simultaneous combination with sorafenib	Preclinical study	Synergistic effects	[97]
EGFR inhibitors
Erlotinib	Simultaneous combination with sorafenib	Phase III (finished)	Not recommended	[109]
c-Met inhibitors
MSC2156119J	Sequential treatment after sorafenib failing	Phase I/II (ongoing)	Awaited	NCT02115373
Tivantinib	Sequential treatment after sorafenib failing	Phase III (ongoing)	Awaited	NCT02029157
	Simultaneous combination with sorafenib	Phase I (finished)	Warranting further clinical study	[118]
DE605	Simultaneous combination with sorafenib	Preclinical study	Synergistic effects	[117]

HDAC: Histone deacetylase; EGFR: Endothelial growth factor receptor.

Citation: Gao JJ, Shi ZY, Xia JF, Inagaki Y, Tang W. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma. World J Gastroenterol 2015; 21(42): 12059-12070
URL: https://www.wjgnet.com/1007-9327/full/v21/i42/12059.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i42.12059